- The Daily Trade
- Posts
- Cavco's Bold $190M Housing Move 🏠
Cavco's Bold $190M Housing Move 🏠
Ryan Serkes
July 15, 2025
The
Daily Trade
Hey Daily Traders,
Cavco Industries is making waves in the housing market with its $190 million acquisition of American Homestar Corporation, a move that underscores its robust financial health and strategic expansion in the South-Central U.S. This acquisition, expected to enhance Cavco’s earnings and operational synergies, reflects the company's confidence in the rising demand for affordable housing.
Kraig Biocraft Laboratories is ramping up its spider silk production with a new facility and innovative silk strains, aiming to boost yields and quality for high-end fabric markets. Meanwhile, Celcuity Inc. secures a patent extension for gedatolisib, its promising breast cancer drug, until 2042, positioning the company to leverage its intellectual property and advance its clinical programs.
Here's what's happening today:
- 🏠 Cavco acquires American Homestar for $190M
- 🕸️ Kraig Labs expands spider silk production
- 💊 Celcuity extends patent for cancer drug
- 🎁 +10 more business & investing news stories you might like
- 📊 +4 technical analysis results
Question
What are your thoughts on Cavco Industries using its cash reserves to acquire American Homestar? Do you see this as a smart strategic move in the affordable housing sector?
Reply to this email with your answer
The Daily Newsletter for Intellectually Curious Readers
Upgrade your news intake with 1440! Dive into a daily newsletter trusted by millions for its comprehensive, 5-minute snapshot of the world's happenings. We navigate through over 100 sources to bring you fact-based news on politics, business, and culture—minus the bias and absolutely free.
Stay informed
Mergers & Acquisitions Cavco Industries, a major player in the factory-built housing market, has announced its acquisition of American Homestar Corporation for $190 million. American Homestar, known for its Oak Creek Homes brand, operates two manufacturing facilities and nineteen retail locations across Texas and surrounding states. The acquisition is expected to close in the third quarter of fiscal year 2026, subject to regulatory approvals. Cavco aims to fund the acquisition entirely from its cash reserves, which signifies its strong financial position. The acquisition is expected to be accretive to Cavco's earnings and cash flow from operations. Cavco anticipates operational and cost synergies through the integration of best practices and optimization opportunities. This strategic move strengthens Cavco's position in the South-Central U.S., a key market for manufactured housing. The deal reflects Cavco's confidence in the growing demand for affordable housing and its commitment to expanding its market presence. Key Takeaway
|
Biotech Kraig Biocraft Laboratories, a leader in spider silk technology, is expanding its production capabilities by adding a second facility and introducing three new advanced spider silk strains. This expansion is part of the company's strategy to enhance production yields and improve silk quality. The new facility will operate in parallel with the existing one, allowing for continuous production by utilizing a diapausing system for silkworms, which enhances silk strength and quality. The company has developed new strains to complement its existing hybrid, improving vigor and yield. These advancements align with Kraig's goal of meeting high-quality standards for premium silk, targeting renowned fabric producers. The expansion is expected to significantly increase production capacity and support the company's long-term vision of establishing a sustainable spider silk production platform. This move positions Kraig to meet growing market demand and strengthen its supply chain resilience. Key Takeaway
|
Pharmaceuticals Celcuity Inc., a clinical-stage biotechnology company, announced the issuance of a new U.S. patent for its lead drug candidate, gedatolisib, extending its patent exclusivity until 2042. This patent covers the clinical dosing regimen for treating ER+/HER2- breast cancer, providing Celcuity with a prolonged period to optimize and develop gedatolisib. The extension strengthens Celcuity's intellectual property portfolio, which already includes multiple patents related to gedatolisib's composition, formulation, and usage. Celcuity is actively conducting clinical trials for gedatolisib, with upcoming topline data announcements expected in 2025. The extended patent protection provides a competitive advantage, allowing Celcuity to focus on advancing its clinical programs and potentially bringing gedatolisib to market. With a robust pipeline and extended exclusivity, Celcuity is well-positioned to capitalize on the growing demand for targeted oncology therapies. Key Takeaway
|
More Business & Investing news
- 🔬 Longevity Health merges with THPlasma (Link)
- 🎰 Churchill Downs acquires Casino Salem stake (Link)
- 🔍 Synopsys gets approval for Ansys acquisition (Link)
- 🏦 Huntington buys Veritex for $1.9 billion (Link)
- ♻️ Casella Waste to acquire Mountain State Waste (Link)
- 💡 Centene faces challenges amid federal cuts (Link)
- 🔋 Eureka Lithium settles outstanding debts (Link)
- 🏢 Nuveen Green Capital funds $9M for apartments (Link)
- 🍬 MariMed expands Betty's Eddies in Maine (Link)
- 🚚 Workhorse in talks for potential transaction (Link)
Today's Technical Analysis
RSI Sell | MFI Sell | WillR Sell | AO Sell |
CCI Sell | BBANDS Sell | ULTOSC Sell | STOCH Sell |
RSI Sell | MFI Sell | WillR Sell | AO Sell |
CCI Sell | BBANDS Sell | ULTOSC Sell | STOCH Sell |
RSI Sell | MFI Sell | WillR Sell | AO Sell |
CCI Sell | BBANDS Sell | ULTOSC Sell | STOCH Sell |
RSI Sell | MFI Sell | WillR Sell | AO Sell |
CCI Sell | BBANDS Sell | ULTOSC Hold | STOCH Sell |
You might also like…
We’re always looking for opportunities to bring our readers more value so we’ve partnered with a handful of companies that we think you might enjoy.
If you have suggestions for companies we should partner with, let us know and we’ll reach out to them.
Do you have an idea for a new website or mobile app?
Under the leadership of tech entrepreneurs, Modern Launch develops software applications from scratch.
Are you looking for your next real estate investment?
Every day, Labrador scans the MLS and runs a cash-flow analysis on every property to deliver only the highest ROI opportunities.
Do you want to try the best wines?
Get weekly wine recommendations from top sommeliers at Pour Decisions.
Want to explore other newsletters?
Take a look at some of the other newsletters our readers love.
Thanks for Reading!
Have ideas to improve our newsletter? Let us know
Want to reach our readers? Become a sponsor
Was this email forwarded to you? Subscribe here
How would you rate today's newsletter?If there's anything I can do better, please reply to this email and let me know! |
Technical Indicator Information
Relative Strength Index (RSI) | Period: 14 days | Overvalued threshold: 70 | Undervalued threshold: 30
Money Flow Index (MFI) | Period: 14 days | Overvalued threshold: 80 | Undervalued threshold: 20
Williams Percent Range (WillR) | Period: 14 days | Overvalued threshold: -20 | Undervalued threshold: -80
Aroon Oscillator (AO) | Period: 14 days | Overvalued threshold: 75 | Undervalued threshold: -75
Moving Average Convergence/Divergence (MACD) | Period: 26/12/9 days | Overvalued threshold: MACD crosses below MACD Signal | Undervalued threshold: MACD crosses above MACD Signal
Stochastic Oscillator (STOCH) | Period: 14/3/3 days | Overvalued threshold: %K crosses below %D above 80 | Undervalued threshold: %K crosses above %D below 20
Commodity Channel Index (CCI) | Period: 20 days | Overvalued threshold: 100 | Undervalued threshold: -100
Bollinger Bands (BBANDS) | Period: 20 days | Overvalued threshold: price >= upper band | Undervalued threshold: price <= lower band
Parabolic Stop and Reverse (SAR) | Period: variable 50 - 100 days | Overvalued threshold: SAR crosses above price | Undervalued threshold: SAR crosses below price
Triple Exponential Average (TRIX) | Period: 15 days | Overvalued threshold: TRIX crosses below 0 | Undervalued threshold: TRIX crosses above 0
Ultimate Oscillator (ULTOSC) | Period: 28/14/7 days | Overvalued threshold: 70 | Undervalued threshold: 30
Directional Movement Index (DMI) | Period: 14 days | Overvalued threshold: PlusDI crosses below MinusDI | Undervalued threshold: PlusDI crosses above MinusDI
Average Directional Index (ADX) | Period: variable 14 days | Requirement: >= 25
Analysis is only performed on securities with market caps in excess of $100 million and with daily trade volume in excess of $50 million.
Disclaimers and Disclosures
The information contained in this newsletter is for informational and educational purposes only and is not intended to constitute investment advice or to address the individual financial circumstances or objectives of any subscriber. Nothing in this publication should be construed as a solicitation, offer, or recommendation to buy or sell any security, investment product, or financial instrument. All opinions expressed herein are solely those of the publisher and are subject to change without notice.
We strongly recommend that you consult with a qualified financial advisor, tax professional, or legal counsel before making any investment decisions. Investing involves risk, including the potential loss of principal. Past performance is not indicative of future results.
Some investment opportunities or companies featured in this newsletter may be presented through paid sponsorships or partnerships. If an opportunity is sponsored or we have a financial relationship with the issuer or promoter, we may or may not disclose this clearly. However, inclusion of any such opportunity does not constitute an endorsement or recommendation, and you should assume that we may have a financial interest in some of the opportunities discussed.
You should not rely solely on the information presented in this newsletter to make any investment decision. You are solely responsible for your own due diligence, investment decisions, and the evaluation of the risks involved. We are not liable for any losses or damages — direct, indirect, incidental, or consequential — arising from any reliance placed on the information in this newsletter, including but not limited to any investment or business decision you make based on such information.
Although we obtain information from sources we believe to be reliable, we do not warrant its accuracy, completeness, or timeliness. Any data, commentary, or analysis may be incomplete, outdated, or not reflect current market conditions, including after-hours trading, material news, or broader economic developments.
This newsletter and all of its content are the proprietary information and property of The Daily Trade and are licensed solely for the personal, individual use of each subscriber. Any unauthorized distribution, reproduction, forwarding, or quotation of the content herein is strictly prohibited.
By reading this newsletter, you agree to the above terms and acknowledge and accept the inherent risks of investing.